ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Has Average Price Target of $99.60

Key Points

• Analysts maintain a neutral outlook: Seven brokerages give ANI Pharmaceuticals an average “Hold” rating, with an average 12-month price target of $99.60 versus the stock’s reported $72.00 price.
• Recent results exceeded expectations: ANI reported quarterly earnings of $2.21 per share, beating estimates of $2.04, while revenue rose 25.8% year over year to $266.04 million.
• Institutional ownership is substantial, while insiders have been selling: Institutions and hedge funds own 76.05% of the stock, while insiders sold 30,412 shares worth approximately $2.22 million over the past 90 days.

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) have been given an average rating of "Hold" by the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $99.60.

ANIP has been the subject of a number of research reports. Canaccord Genuity Group lowered their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a report on Monday, August 10th. Guggenheim dropped their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a research note on Monday, August 10th. Oppenheimer began coverage on ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They issued a "market perform" rating and a $85.00 price target on the stock. Weiss Ratings lowered shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Tuesday, August 11th. Finally, Wall Street Zen cut ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, CEO Nikhil Lalwani sold 5,400 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $71.89, for a total transaction of $388,206.00. Following the transaction, the chief executive officer owned 333,689 shares of the company's stock, valued at $23,988,902.21. This represents a 1.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeanne Thoma sold 1,000 shares of the company's stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $71.53, for a total transaction of $71,530.00. Following the completion of the transaction, the director owned 26,762 shares in the company, valued at approximately $1,914,285.86. This trade represents a 3.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 30,412 shares of company stock valued at $2,220,970 in the last ninety days. 8.10% of the stock is owned by insiders.

Institutional Trading of ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Ranger Investment Management L.P. acquired a new position in ANI Pharmaceuticals in the second quarter worth about $28,406,000. Deutsche Bank AG acquired a new position in shares of ANI Pharmaceuticals during the second quarter worth about $26,775,000. William Blair Investment Management LLC acquired a new position in shares of ANI Pharmaceuticals in the second quarter valued at about $21,372,000. Parkman Healthcare Partners LLC acquired a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $16,797,000. Finally, Bank of America Corp DE purchased a new position in shares of ANI Pharmaceuticals during the second quarter valued at approximately $15,154,000. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $72.00 on Monday. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of 15.52, a price-to-earnings-growth ratio of 2.32 and a beta of 0.45. The stock's fifty day moving average is $72.96 and its 200-day moving average is $77.68. ANI Pharmaceuticals has a one year low of $69.58 and a one year high of $95.57. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.17. The firm had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%. The company's quarterly revenue was up 25.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts anticipate that ANI Pharmaceuticals will post 7.76 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI's portfolio includes branded products and generic medicines, as well as treatments for rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.